Angiogénese
Os inibidores da angiogênese são compostos que interferem na formação de novos vasos sanguíneos, um processo crítico no crescimento e metástase do câncer. Ao inibir a angiogênese, esses compostos podem restringir o suprimento de sangue para os tumores, retardando ou interrompendo seu crescimento. Os inibidores da angiogênese são essenciais na pesquisa do câncer e no desenvolvimento terapêutico, fornecendo insights sobre os mecanismos de progressão tumoral e oferecendo potenciais tratamentos para o câncer e outras doenças relacionadas à angiogênese. Na CymitQuimica, oferecemos uma ampla gama de inibidores da angiogênese de alta qualidade para apoiar sua pesquisa em oncologia e biologia vascular.
Subcategorias de "Angiogénese"
- BTK(166 produtos)
- Bcr-Abl(117 produtos)
- EGFR(572 produtos)
- FAK(72 produtos)
- FLT(86 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(178 produtos)
- JAK(244 produtos)
- PDGFR(127 produtos)
- RAAS(86 produtos)
- Src(82 produtos)
- Syk(37 produtos)
- Trombina(56 produtos)
- VDA(2 produtos)
- VEGFR(239 produtos)
Exibir 6 mais subcategorias
Foram encontrados 2342 produtos de "Angiogénese"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
PP487
CAS:PP487 is a dual tyrosine kinase/PI(3)K inhibitor, exhibiting IC50 values of 0.017 μM, 0.072 μM, 0.004 μM, 0.01 μM, 0.55 μM, 0.22 μM, and < 0.01 μM against DNA-PK, mTOR, Hck, Src, EGFR, EphB4, and PDGFR, respectively. It is applicable in cancer research [1].Fórmula:C14H14BrN5OCor e Forma:SolidPeso molecular:348.2EGFR-IN-133
CAS:EGFR-IN-133 (Compound 24) serves as an inhibitor targeting various mutations of the EGFR, including the wild type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with respective IC50 values of 0.1, 0.044, 0.036, 0.04, and 0.054 nM. The compound exhibits favorable pharmacokinetic properties and high oral bioavailability.Fórmula:C27H29F2N7O3Cor e Forma:SolidPeso molecular:537.56(3S,4R)-Tofacitinib
CAS:(3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib is a JAK3 inhibitor(IC50 : 1 nM).Fórmula:C16H20N6OPureza:98%Cor e Forma:SolidPeso molecular:312.37BTK-IN-32
CAS:BTK-IN-32 (compound C2) acts as a potent BTK inhibitor. Unlike isolated kinase domains, this compound activates full-length BTK as well as its smaller multidomain fragments [1].Fórmula:C35H35ClN4O3SCor e Forma:SolidPeso molecular:627.2EGFR-IN-62
EGFR-IN-62: IC50 of 10-242 nM for various EGFR mutations, blocks A549/H1975 cell cycle, induces apoptosis, and inhibits cell motility and proliferation.Fórmula:C30H33N9O2Cor e Forma:SolidPeso molecular:551.64PF-06463922 acetate
CAS:PF-06463922 acetate: ALK/ROS1 inhibitor, brain- penetrable, active vs crizotinib-resistant mutants, in NSCLC trials.Fórmula:C23H23FN6O4Cor e Forma:SolidPeso molecular:466.46EGFR-IN-130
EGFR-IN-130 (compound 14b) is an EGFR inhibitor and an inducer of apoptosis (apoptoosis). It effectively kills HeLa cancer cells by inducing apoptosis.Fórmula:C27H25N3O6SCor e Forma:SolidPeso molecular:519.57DBMB
CAS:DBMB is a spleen tyrosine kinase (Syk) inhibitor that significantly suppresses Syk enzyme activity. It possesses anti-inflammatory properties by inhibiting NF-κB signaling, thereby reducing the production of inflammatory mediators such as nitric oxide (NO) and prostaglandin E2 (PGE2). DBMB can be utilized in research on inflammatory diseases.Fórmula:C24H22N4OCor e Forma:SolidPeso molecular:382.458BMS-066
CAS:BMS-066 is an IKKβ/Tyk2 pseudokinase inhibitor. With IC50s of 9 nM and 72 nM, respectively.Fórmula:C19H21N7O2Pureza:98%Cor e Forma:SolidPeso molecular:379.42AJI-214
CAS:AJI-214 functions as a dual-target inhibitor that specifically blocks Aurora kinase A and JAK2. By directly inhibiting Aurora kinase A, AJI-214 prevents mitotic progression and cell polarity in T cells while concurrently suppressing JAK2 activation to reduce STAT3 phosphorylation. This inhibition decreases the differentiation of TH1 and TH17 cells. AJI-214 is utilized in research focused on the modulation of immune responses and the prevention of graft-versus-host disease (GVHD).Fórmula:C17H13ClFN5OCor e Forma:SolidPeso molecular:357.77Pyk2-IN-2
CAS:Pyk2-IN-2 (compound 13j) acts as a Pyk2 inhibitor, exhibiting an IC 50 value of 0.608 μM for FAK kinase [1].Fórmula:C27H27N7OCor e Forma:SolidPeso molecular:465.55VEGFR-2-IN-16
VEGFR-2-IN-16 (Compound 15b) is a potent inhibitor of VEGFR-2 (IC50: 86.36 nM) that exhibits antitumour effects.Fórmula:C21H13Cl2N3O2Cor e Forma:SolidPeso molecular:410.25PF-06263276
CAS:PF-06263276 selectively inhibits pan-JAK with IC50: JAK1 (2.2 nM), JAK2 (23.1 nM), JAK3 (59.9 nM), TYK2 (29.7 nM).Fórmula:C31H31FN8O2Pureza:98%Cor e Forma:SolidPeso molecular:566.63EGFR-IN-161
CAS:EGFR-IN-161 (Compound DD-8) is a potent and reversible inhibitor of the L858R/T790M/C797S mutant EGFR kinase, with an IC50 value of 0.87 nM. EGFR-IN-161 effectively inhibits tumor cell apoptosis, G1 phase arrest, and migration.Fórmula:C33H36Cl2N8O2Cor e Forma:SolidPeso molecular:647.597CP-352664
CAS:CP-352664 is a JAK inhibitor with potency against JAK3, exhibiting an EC50 value of 210 nM. It holds potential for use in research related to organ transplant rejection and autoimmune diseases, such as rheumatoid arthritis.Fórmula:C18H18N4Cor e Forma:SolidPeso molecular:290.36EGFR/VEGFR2-IN-3
CAS:EGFR/VEGFR2-IN-3 (compound 9) is an effective inhibitor of EGFR and VEGFR-2, demonstrating IC50 values of 0.129 µM for EGFR, 0.142 µM for VEGFR-2, and 3.428 µM for COX-2. This compound exhibits cytotoxic properties and induces cell apoptosis (apoptosis) as well as cell cycle arrest at the G2/M phase.Fórmula:C24H20ClN5O2S2Cor e Forma:SolidPeso molecular:510.03Tandutinib sulfate
CAS:Tandutinib (MLN518) sulfate is an effective and selective inhibitor of FLT3, with an IC50 value of 0.22 μM. It also inhibits c-Kit and PDGFR, displaying IC50 values of 0.17 μM and 0.20 μM respectively. This compound can be utilized in the treatment of acute myeloid leukemia and has the capability to cross the blood-brain barrier.Fórmula:C31H44N6O8SCor e Forma:SolidPeso molecular:660.78FGFR1 inhibitor-6
FGFR1 inhibitor-6, IC50: 16.31 nM, blocks cell cycle at pro-G1/G2/M and induces apoptosis.Fórmula:C27H19N5O4S2Cor e Forma:SolidPeso molecular:541.6Tesevatinib tosylate
CAS:Tesevatinib tosylate (XL-647 tosylate) is an orally administered epidermal growth factor receptor (EGFR) inhibitor that can cross the blood-brain barrier. It significantly reduces cell viability with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Additionally, Tesevatinib tosylate inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM), demonstrating antitumor activity by inhibiting tumor proliferation.Fórmula:C31H33Cl2FN4O5SCor e Forma:SolidPeso molecular:663.59EGFR-IN-18
EGFR-IN-18 strongly inhibits L858R/T790M/C797S mutant EGFR (4.9 nM) and also targets wild-type EGFR (47 nM).Fórmula:C33H28N6O3SCor e Forma:SolidPeso molecular:588.68JAK3/BTK-IN-7
CAS:JAK3/BTK-IN-7 (XL-12), characterized as a JAK3/BTK inhibitor, exhibits IC 50 values of 2 nM and 14 nM for JAK3 and BTK respectively. This compound demonstrates anti-inflammatory properties and is applicable in research related to rheumatoid arthritis [1].Fórmula:C29H30N8O4Cor e Forma:SolidPeso molecular:554.6Vecabrutinib
CAS:Vecabrutinib (SNS-062) is a potent and noncovalent BTK and ITK inhibitor (Kd: 0.3 nM and 2.2 nM, respectively). Vecabrutinib displays an IC50 of 24 nM for ITK.Fórmula:C22H24ClF4N7O2Pureza:99.74%Cor e Forma:SolidPeso molecular:529.92Ref: TM-T17220
1mg82,00€5mg177,00€10mg289,00€25mg470,00€50mg623,00€100mg874,00€1mL*10mM (DMSO)207,00€Vatalanib hydrochloride
CAS:Vatalanib hydrochloride (PTK787 hydrochloride) is an orally available and highly potent tyrosine kinase (VEGF) inhibitor that reduces the number and size of Aβ plaques in the cortex of 5xFAD mice, which may be useful in the study of Alzheimer's disease and cancer.Fórmula:C20H16Cl2N4Pureza:99.7%Cor e Forma:SolidPeso molecular:383.27NDI-034858
CAS:NDI-034858 (TAK-279) is a tyrosine kinase 2 (TYK2) inhibitor (Kd<200 pM) that targets the JH2 structural domain of Tyk2 for the treatment of autoimmune diseasesFórmula:C23H24N8O3Pureza:>99.99%Cor e Forma:SolidPeso molecular:460.49XMD-17-51 Trifluoroacetate
CAS:XMD-17-51 Trifluoroacetate is a pyrimido-diazepinone compound that regulates protein kinases.Fórmula:C23H25F3N8O3Pureza:99.65%Cor e Forma:SolidPeso molecular:518.49JAK2-IN-7
CAS:JAK2-IN-7 selectively inhibits JAK2 (IC50: 3 nM), shows 14-fold selectivity over JAK1/3, FLT3, induces G0/G1 arrest, apoptosis, and has antitumor effects.Fórmula:C26H33N7OPureza:99.54%Cor e Forma:SolidPeso molecular:459.59Ref: TM-T35900
1mg138,00€5mg334,00€10mg597,00€25mg1.234,00€50mg1.648,00€100mg2.232,00€1mL*10mM (DMSO)339,00€JDTic
CAS:JDTic, a 4-phenylpiperidine derivative distantly related to analgesics like meperidine and ketobemidone and more closely to the mu opioid antagonist alvimopan, exhibits a notably long duration of action, maintaining effects in animals for weeks following a single dose. This duration is not due to irreversible binding to the kappa opioid receptor but rather to altered activity of c-Jun N-terminal kinases. As a highly selective antagonist for the κ-opioid receptor, without influencing the μ- or δ-opioid receptors, JDTic has shown potential in animal studies for producing antidepressant and anxiolytic effects. It also demonstrates promise in treating addiction to substances such as cocaine and morphine, distinguishing itself structurally from other kappa antagonists like norbinaltorphimine.Fórmula:C28H39N3O3Cor e Forma:SolidPeso molecular:465.63Ibrutinib Racemate
CAS:Ibrutinib is a selective, irreversible Btk inhibitor (IC50: 0.5 nM). Ibrutinib Racemate is the racemate of Ibrutinib.Fórmula:C25H24N6O2Pureza:98%Cor e Forma:SolidPeso molecular:440.5Dihydrodiol-Ibrutinib
CAS:PCI 45227 is an active metabolite of the Bruton's tyrosine kinase inhibitor ibrutinib .1PCI 45227 is formed from ibrutinib by the cytochrome P450 (CYP) isoform CYP3A. 1.Veeraraghavan, S., Viswanadha, S., Thappali, S., et al.Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: Application to a pharmacokinetic studyJ. Pharm. Biomed. Anal.107151-158(2015)Fórmula:C25H26N6O4Cor e Forma:SolidPeso molecular:474.521Nimotuzumab (powder)
CAS:Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), possessing a dissociation constant (KD) of 0.21 nM. It blocks the binding to its ligand by targeting the extracellular domain of EGFR. Nimotuzumab exhibits strong antitumor activity by inducing both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), exerting cytolytic effects on target tumors.
Cor e Forma:LiquidXMU-MP-3
CAS:XMU-MP-3 is a robust, non-covalent inhibitor of BTK, exhibiting exceptional potency with IC50 values of 10.7 nM and 17.0 nM for BTK WT and BTK C481S mutation, respectively, in the presence of 10 μM ATP. Moreover, XMU-MP-3 elicits apoptosis.Fórmula:C27H27F3N8OCor e Forma:SolidPeso molecular:536.563PM-8002
PM-8002 is a bispecific antibody that targets PD-L1 and VEGF-A. It is applicable for research on solid tumors.
Cor e Forma:Odour LiquidENMD-2076 tartrate
CAS:ENMD-2076 is an orally active kinase inhibitor. It also has antiangiogenic and antiproliferative mechanisms of action.Fórmula:C25H31N7O6Cor e Forma:SolidPeso molecular:525.56Imbotolimod
Imbotolimod, a humanized monoclonal antibody of the immunoglobulin G1-kappa class, exhibits both anti-ERBB2 and antineoplastic activities.Cor e Forma:Odour LiquidTLC9995-0188
CAS:Tyrosine-protein kinase ABL, IC50: 1500 nMFórmula:C16H15N5Cor e Forma:Yellow SolidPeso molecular:277.331(3R,4S)-Tofacitinib
CAS:(3R,4S)-Tofacitinib, the less active enantiomer of Tofacitinib, is a JAK3 inhibitor with an IC50 of 1 nM.Fórmula:C16H20N6OPureza:98%Cor e Forma:SolidPeso molecular:312.37HMBD-001
HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor that targets HER3. By inhibiting the dimerization of HER3, HMBD-001 suppresses the growth and proliferation of tumor cells. It holds potential for research in cancer treatments, specifically for pancreatic cancer and non-small cell lung cancer.
Cor e Forma:Odour LiquidOlmutinib
CAS:Olmutinib (BI1482694) is a Novel Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorFórmula:C26H26N6O2SPureza:99.14%Cor e Forma:SolidPeso molecular:486.59Desidustat
CAS:Desidustat is an inhibitor of HIF hydroxylase.
Fórmula:C16H16N2O6Pureza:98%Cor e Forma:SolidPeso molecular:332.31Duligotuzumab
CAS:Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, solid tumours, head and neck cancer,colorectal cancer.
Pureza:95%Cor e Forma:LiquidRef: TM-T80604
Produto descontinuado3,3',4,4'-Tetrabromobiphenyl
CAS:Produto ControladoApplications 3,3',4,4'-Tetrabromobiphenyl is multi-persistent organic pollutants analyzed in breast milk of first time mothers. An environmental pollutant that affects copper and molybdenum metabolism in rats. Also, it is derived from 1-Bromo-2- nitrobenze (B686175), which is an organic building block used for the synthesis of various pharmaceutical compounds. It is an intermediate for the synthesis of novel Diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity.
References Tlustos, C., et al.: Organohalogen Compd., 75, 1185-1188 (2013); Salman, K. N., et al.: Environ. Sci. Pollut. R., 21, 6400-6409 (2014); Dao, P., et al.: Bioorg. Med. Chem. Lett., 23, 4552 (2013);Fórmula:C12H6Br4Cor e Forma:Off-White To Light BrownPeso molecular:469.79
